GNPX (Genprex, Inc. Common Stock)
Insider Trading Activity
Every open-market purchase and sale reported by GNPX officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-04-15 | BRENT M LONGNECKER | Director | Sell | — | — |
| 2026-02-27 | Mark Stanley Berger | Chief Medical Officer | F | — | — |
| 2026-02-27 | Ryan M. Confer | President, CEO and CFO | F | — | — |
| 2025-12-23 | BRENT M LONGNECKER | Director | A | — | — |
| 2025-12-23 | William R Wilson Jr. | Director | A | — | — |
| 2025-12-23 | Toscano Jose Antonio Moreno | Director | A | — | — |
| 2025-12-23 | Mark Stanley Berger | Chief Medical Officer | A | — | — |
| 2025-12-23 | Ryan M. Confer | President, CEO and CFO | A | — | — |
| 2025-07-01 | Mark Stanley Berger | Chief Medical Officer | F | — | — |
| 2025-07-01 | Ryan M. Confer | President, CEO and CFO | F | — | — |
| 2025-02-19 | Mark Stanley Berger | Chief Medical Officer | F | — | — |
| 2025-02-19 | Ryan M. Confer | President, CEO and CFO | F | — | — |
| 2024-12-06 | Ryan M. Confer | President, CEO and CFO | A | — | — |
| 2024-12-06 | Mark Stanley Berger | Chief Medical Officer | A | — | — |
| 2024-12-06 | William R Wilson Jr. | Director | A | — | — |
| 2024-12-06 | Toscano Jose Antonio Moreno | Director | A | — | — |
| 2024-12-06 | BRENT M LONGNECKER | Director | A | — | — |
| 2024-02-21 | Mark Stanley Berger | Chief Medical Officer | F | — | — |
| 2024-02-21 | Ryan M. Confer | Chief Financial Officer | F | — | — |
| 2024-02-21 | John Rodney Varner | Chairman, President and CEO | F | — | — |
| 2023-06-29 | BRENT M LONGNECKER | Director | A | — | — |
| 2023-06-29 | William R Wilson Jr. | Director | A | — | — |
| 2023-06-29 | Toscano Jose Antonio Moreno | Director | A | — | — |
| 2023-04-24 | CATHERINE M VACZY | EVP GC Chief Strategy Officer | Buy | — | — |
| 2023-04-24 | John Rodney Varner | Chairman, President and CEO | Buy | — | — |
| 2023-02-22 | CATHERINE M VACZY | EVP GC Chief Strategy Officer | A | — | — |
| 2023-02-22 | Hermant Kumar | Chief Mfgr & Tech Officer | A | — | — |
| 2023-02-22 | John Rodney Varner | President & CEO | A | — | — |
| 2023-02-22 | Ryan M. Confer | Chief Financial Officer | A | — | — |
| 2023-02-22 | Mark Stanley Berger | Chief Medical Officer | A | — | — |
| 2022-08-01 | Ryan M. Confer | Chief Financial Officer | M | — | — |
| 2022-06-27 | William R Wilson Jr. | Director | A | — | — |
| 2022-06-27 | Hermant Kumar | Chief Mfgr & Tech Officer | A | — | — |
| 2022-06-27 | BRENT M LONGNECKER | Director | A | — | — |
| 2022-06-27 | Toscano Jose Antonio Moreno | Director | A | — | — |
| 2022-02-08 | Hermant Kumar | Chief Mfgr & Tech Officer | A | — | — |
| 2022-02-08 | John Rodney Varner | President & CEO | A | — | — |
| 2022-02-08 | Mark Stanley Berger | Chief Medical Officer | A | — | — |
| 2022-02-08 | CATHERINE M VACZY | EVP GC Chief Strategy Officer | A | — | — |
| 2022-02-08 | Ryan M. Confer | Chief Financial Officer | A | — | — |
| 2021-09-28 | Hermant Kumar | Chief Mfgr & Tech Officer | A | — | — |
| 2021-09-28 | Mark Stanley Berger | Chief Medical Officer | A | — | — |
| 2021-06-25 | BRENT M LONGNECKER | Director | A | — | — |
| 2021-06-25 | William R Wilson Jr. | Director | A | — | — |
| 2021-06-25 | Toscano Jose Antonio Moreno | Director | A | — | — |
| 2021-04-07 | BRENT M LONGNECKER | Director | Buy | — | — |
| 2021-03-23 | Ryan M. Confer | Chief Financial Officer | A | — | — |
| 2021-03-23 | John Rodney Varner | President & CEO | A | — | — |
| 2021-03-23 | CATHERINE M VACZY | EVP GC Chief Strategy Officer | A | — | — |
| 2021-03-23 | Michael Thomas Redman | EVP & Chief Operating Officer | A | — | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| — | President, CEO and CFO | 1,651 | — |
| — | Chief Medical Officer | 986 | — |
| — | Director | 416 | — |
| — | Director | 416 | — |
| — | Director | 416 | — |
| — | 10%+ Owner | 68 | — |
| — | 10%+ Owner | 54 | — |
| — | Chairman, President and CEO | 24 | — |
| — | EVP GC Chief Strategy Officer | 6 | — |
| — | Chief Mfgr & Tech Officer | 5 | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the GNPX quote page; the site-wide leaderboard is on the insider transactions hub.